Neuropeptide S (NPS): NPSR1 Receptor Pharmacology, Anxiolytic-Arousal Research, and Fear Extinction Evidence

Neuropeptide S is a twenty-residue brainstem peptide, sequence SFRNGVGTGMKKTSFQRAKS in humans, that acts at a single G protein-coupled receptor, NPSR1, and neuropeptide S research is defined by one unusual finding: central administration is simultaneously anxiolytic and arousal-promoting. That combination separates it from benzodiazepines, which reduce anxiety while suppressing locomotion and promoting sleep. The peptide was deorphanised in 2004 and the literature since has concentrated on fear extinction, memory consolidation and the genetics of the receptor. Neuropeptide S is a reference compound discussed here for its pharmacology; it is not an item in the Maple Research Labs catalogue.

Disclaimer: For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use. The information presented here is drawn from published scientific literature and is intended solely for educational reference.

Sequence, Origin and Receptor

Human neuropeptide S is the twenty-residue product of the NPS precursor, UniProt P0C0P6, with the mature sequence Ser-Phe-Arg-Asn-Gly-Val-Gly-Thr-Gly-Met-Lys-Lys-Thr-Ser-Phe-Gln-Arg-Ala-Lys-Ser and a calculated average mass of approximately 2187.5 Da. The name comes from the invariant N-terminal serine. An earlier version of this page gave a twenty-residue sequence beginning Ser-Arg-Asn-Leu that corresponds to no published neuropeptide S from any species, and it has been replaced. The distinction is not academic: a peptide synthesised to the wrong sequence has a different mass, and a mass spectrum that confirms the wrong target is worse than no mass spectrum at all.

Xu and colleagues reported the peptide and its receptor in Neuron (2004, 43:487-497, PMID 15312648), not in Cell as this page previously stated. That paper established the core profile: NPS activates its cognate receptor with mobilisation of intracellular calcium, NPSR mRNA is widely distributed in brain including amygdala and midline thalamic nuclei, central administration increases locomotor activity in mice and decreases both paradoxical and slow wave sleep in rats, and NPS produced anxiolytic-like effects across four separate stressful paradigms. The anatomical finding that has shaped the field since is that NPS-expressing cells sit in a previously undefined cluster between the locus coeruleus and Barrington’s nucleus, placing the peptide inside the brainstem arousal system rather than adjacent to it.

Leonard and colleagues (Psychopharmacology 2008, 197:601-611, PMID 18311561) extended the in vitro and behavioural characterisation in mouse. Mouse NPS 1-20 bound the mouse receptor with a Ki of 0.203 plus or minus 0.060 nM and activated intracellular calcium release with an EC50 of 3.73 plus or minus 1.08 nM; the C-terminally truncated NPS 1-19 was comparable at 0.635 nM and 4.10 nM. Anxiolytic-like activity appeared in the four-plate test, the elevated zero maze and stress-induced hyperthermia, in each case at minimal effective doses well below those of the reference anxiolytics alprazolam and chlordiazepoxide. The negative result matters as much as the positive ones: NPS did not alter immobility time in the tail suspension test, so the profile is anxiolytic rather than antidepressant. An earlier version of this page attributed elevated plus maze percentages and locomotor figures to a 2007 Neuropharmacology paper by Leonard and Bhave that could not be located.

The Asn107Ile Receptor Variant

NPSR1 carries a common human polymorphism at position 107 in the first extracellular loop, substituting isoleucine for asparagine. Reinscheid and colleagues (Journal of Pharmacology and Experimental Therapeutics 2005, 315:1338-1345, PMID 16144971) characterised the variants and found that Ile107 is a gain-of-function change: agonist potency increases while binding affinity is unchanged. That specific combination points to altered receptor activation rather than altered ligand recognition. The same study found that the C-terminal splice variant behaves like Asn107, and that the mouse receptor, which natively carries Ile107, sits at an intermediate profile. Structure-activity work in that paper identified the amino terminus of NPS as critical for receptor activation, which is consistent with the N-terminal serine being invariant.

The human genetics have been examined directly. Donner and colleagues (Biological Psychiatry 2010, 68:474-483, PMID 20705147) tested variants in NPS and NPSR1 across a Finnish population sample of 321 anxiety disorder patients and 1317 controls, a Spanish panic disorder panel of 188 cases and 315 controls, and a Swedish birth cohort of 2020 children. Single nucleotide polymorphisms in both genes associated with panic disorder diagnosis in the Finnish and Spanish samples and with parent-reported anxiety or depression in the birth cohort, and some of the implicated variants altered DNA-protein complex formation in electrophoretic mobility shift assays. In stressed Npsr1 knockout mice, neurotrophin-3 expression was significantly downregulated and interleukin-1 beta upregulated in brain regions of interest. The same paper confirmed the epidemiological association between anxiety and asthma in two population cohorts, which is the observation that originally linked NPSR1 to two apparently unrelated phenotypes.

Arousal and the Sleep-Wake Mechanism

The wake-promoting action has a mapped hypothalamic substrate. In rats given intracerebroventricular NPS at 0.1 and 1 nmol (Neuroscience 2012, 207:218-226, PMID 22300983), wakefulness over the first two hours rose to 54.7 plus or minus 3.2 and 64.9 plus or minus 2.1 minutes respectively against 41.4 plus or minus 2.5 minutes with saline, with EEG high frequency activity between 14.5 and 60 Hz increased and both slow wave and paradoxical sleep significantly reduced. Ex vivo c-Fos immunohistochemistry localised the effect: expression rose in histaminergic neurons by 76.0 percent in the ventral tuberomammillary nucleus and 57.8 percent in the dorsal tuberomammillary nucleus, and in orexinergic neurons by 28.2 percent in the perifornical nucleus, 24.3 percent in the dorsomedial hypothalamic nucleus and 13.7 percent in the lateral hypothalamic area. Since NPSR mRNA is highly expressed in both populations, the straightforward reading is that NPS drives wakefulness by recruiting the histaminergic and orexinergic arms of the ascending arousal system. Researchers comparing arousal mechanisms across peptide systems may find the orexin-A receptor research summary a useful companion, since that system is the one being recruited here.

An earlier version of this page reported prefrontal norepinephrine and amygdalar serotonin microdialysis percentages attributed to Slattery and colleagues. No such study could be located and those figures have been removed. The noradrenergic involvement that is documented comes from the memory work below, where propranolol blocks the effect.

Fear Extinction and the Amygdala

The most cited mechanistic result in this literature is Jungling and colleagues (Neuron 2008, 59:298-310, PMID 18667157). Administered into the amygdala in mice, NPS produced anxiolytic effects and facilitated extinction of conditioned fear responses, and an NPSR antagonist produced functionally opposite responses, which is the observation that implicates endogenous NPS tone in both anxiety behaviour and extinction rather than only exogenous peptide. The cellular mechanism reported is specific and is worth stating correctly, because this page previously described the basolateral amygdala as the sole locus. NPS increases glutamatergic transmission onto intercalated GABAergic neurons of the amygdala, acting through presynaptic NPS receptors on the principal neurons that connect to them. The intercalated cell masses are the inhibitory gate between basolateral input and central amygdala output, so an agonist that increases their drive suppresses fear output without acting directly on the output nucleus.

Freezing percentages, group sizes and a stress-enhanced fear learning study attributed to Souza and colleagues in 2011 appeared in an earlier version of this page and could not be traced to any located source. They have been removed rather than reassigned, since the mechanism above stands on its own without them.

Memory Consolidation

Okamura and colleagues (Neuropsychopharmacology 2011, 36:744-752, PMID 21150909) tested whether NPS modulates acquisition, consolidation or recall using inhibitory avoidance and novel object recognition. Immediate and delayed post-training central administration dose-dependently enhanced retention in mice, while pre-training and pre-test injections were ineffective, which localises the action to the consolidation window rather than to learning or retrieval. A synthetic NPSR antagonist given peripherally attenuated the enhancement, establishing pharmacological specificity. NPSR knockout mice showed deficits in inhibitory avoidance, novel object recognition and novel place or context recognition, so endogenous signalling is required for normal memory formation and not merely capable of augmenting it. Propranolol attenuated the NPS-induced enhancement, implicating central noradrenergic systems. The authors read the result as NPS acting as a salience or arousal signal rather than as a content-specific memory mechanism, which fits the enhancement being independent of whether the task was aversive.

Morris water maze acquisition figures attributed to Meis and colleagues in 2008 and a long-term potentiation magnitude in area CA1 appeared in an earlier version of this page. The 2008 Meis paper is a PLoS One study of a neuropeptide S responsive circuit shaping amygdala activity via the endopiriform nucleus, not a spatial memory study, and those claims have been removed.

Antagonist Tools

SHA 68 is the small-molecule antagonist the field relies on, reported by Okamura and colleagues in the Journal of Pharmacology and Experimental Therapeutics (2008, 325:893-901, PMID 18337476), not in the Proceedings of the National Academy of Sciences as previously stated here. Its chemical name is 3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide, and the closely related benzylamide analogue SHA 66 was described in the same paper; an earlier version of this page gave an isoquinolinyloxy-phenyl-methanol structure that belongs to a different compound entirely. SHA 68 blocks NPS-induced calcium mobilisation, shows displaceable binding to NPSR in the nanomolar range, and does not affect signalling at fourteen unrelated G protein-coupled receptors. Pharmacokinetic analysis showed it reaches relevant plasma and brain levels after intraperitoneal administration, and at 50 mg/kg intraperitoneally in mice it antagonised NPS-induced horizontal activity, vertical activity and stereotypic behaviour. The selectivity panel size and a specific rat Ki previously given on this page were not in that paper.

Later medicinal chemistry has expanded the toolkit. A structure-activity and X-ray crystallography study of NPS antagonists appeared in ACS Chemical Neuroscience (2014, 5:731-744, PMID 24964000), and a biased NPSR agonist retaining anxiolytic and memory-promoting activity was reported in Neuropharmacology (2017, 118:69-78, PMID 28267583), which raises the possibility of separating the anxiolytic and arousal components that have travelled together since 2004.

Handling and Analytical Considerations

Neuropeptide S is a linear twenty-mer with no disulfide bonds and no unusual residues, so it is a routine solid-phase synthesis target. The practical constraints are the ones common to linear peptides of this length. Repeated freeze-thaw cycling should be avoided, reconstitution is normally into sterile saline or phosphate-buffered saline near neutral pH immediately before use, and lyophilised material is held sealed at minus twenty degrees Celsius or below for long-term storage. Identity should be confirmed by mass spectrometry against the calculated mass for the correct sequence, and purity by integrated HPLC peak area at a stated wavelength, before any receptor binding or behavioural series. The reason is specific to this peptide: the amino terminus is the part of the molecule required for receptor activation, so N-terminally truncated impurities are the ones most likely to behave as partial agonists and distort a concentration-response curve. General methodology is set out in the discussion of HPLC testing for peptide purity and in the treatment of mass spectrometry for identity confirmation. An earlier version of this page referred to aminopeptidase cleavage at a Ser1-Arg2 bond, a bond that does not exist in the real sequence, where position 2 is phenylalanine.

Where a batch of a compound in our catalogue has been tested, the independent laboratory report is published on the certificates of analysis page, which also lists the compounds still awaiting a report. Neuropeptide S is not a catalogue compound, and an earlier version of this page implied otherwise. The research peptide catalogue and the documentation section cover the compounds that are.

Related Peptide Systems

Anxiolysis without sedation is claimed in more than one peptide literature, and the mechanisms are unrelated. Selank and its tuftsin-derived mechanisms reach a comparable behavioural description through GABAergic modulation and enkephalin degradation rather than through NPSR1. Stress-modulating peptide signalling in the same limbic circuits is also covered in the neuropeptide Y research summary, a separate system with its own receptor family that is frequently confused with this one on the basis of the name alone.

Citations in this article were checked against the indexed PubMed record and, for the peptide sequence, against UniProt P0C0P6 on 20 September 2026. Corrections made in this revision: the primary sequence, the journal for the 2004 discovery paper, the journal and chemical structure for SHA 68, the amygdala mechanism in Jungling 2008, and the replacement of untraceable citations attributed to Leonard and Bhave 2007, Slattery, Souza 2011 and Meis 2008 with the primary studies that report the underlying findings.

Related research resources: further reading on substance P and NK1 receptor research, galanin receptor research and vasopressin receptor pharmacology.

For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.